The company reported positive Phase 3 results for CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD, meeting its primary endpoint and showing dose-dependent improvements with rapid onset and sustained symptom relief up to 12 hours post-dose. Cingulate is preparing commercial infrastructure with partner Indegene, pending FDA approval, positioning itself for a competitive entry into the ADHD treatment market.
Cyborg Score Rationale
The FDA accepted the New Drug Application in October 2025 with a target PDUFA date of May 31, 2026, de-risking the lead candidate. The company secured an exclusive U.S. supply agreement with Bend Bio Sciences and has strong analyst support, though near-term cash constraints require ongoing financing.
Top Insights
Positive Phase 3 pediatric ADHD data showed primary endpoint met with safety/tolerability consistent with stimulant class
Analyst consensus is "Strong Buy" with 12-month price target of $31.33, representing 415% upside from recent prices
Recently closed $12.0 million at-the-market financing in January 2026 at $5.04 per share
Pipeline includes CTx-2103 (buspirone) for anxiety and CTx-1302 (dextroamphetamine) for ADHD expansion
Named Competitors
Adhansia XR — Long-acting amphetamine combination for ADHD